Zepbound and Opioids (Oxycodone, Hydrocodone, Tramadol): Interaction Risk Explained

Is there a known interaction between Zepbound and opioids?

The Zepbound label does not list one. Its drug interactions section has two parts: insulin and insulin secretagogues such as sulfonylureas, where the concern is low blood sugar, and oral medications [1]. The oral-medication part says tirzepatide delays gastric emptying and has the potential to affect absorption of oral drugs, advises caution when oral drugs are given with Zepbound, and says to monitor drugs that depend on threshold concentrations for efficacy or that have a narrow therapeutic index, naming warfarin as the example [1].

Oxycodone, hydrocodone and tramadol are not among the drugs named in that section. The label quantifies absorption changes for acetaminophen and for a combined oral contraceptive. For hormonal contraceptives it advises switching to a non-oral method or adding a barrier method for 4 weeks after starting Zepbound and for 4 weeks after each dose escalation [1].

How big is the gastric-emptying effect, and how long does it last?

Tirzepatide is a dual GIP and GLP-1 receptor agonist given once weekly, with a half-life of about 5 days [1]. The label states that the delay in gastric emptying is largest after the first dose and diminishes over time [1].

The clearest measurement in the label for a non-contraceptive drug comes from acetaminophen. After a first 5 mg dose of tirzepatide, acetaminophen peak concentration (Cmax) fell 55% and time to peak (Tmax) was 1 hour later. By week 6, on the 15 mg dose, there was no meaningful effect on acetaminophen Cmax or Tmax, and total exposure (AUC) was unchanged [1].

Acetaminophen is not an opioid. It shows the direction and the time course of the absorption effect, not what happens to any particular opioid.

Does Zepbound change how fast oxycodone, hydrocodone or tramadol work?

The label reports no measurement of how tirzepatide affects the onset, blood levels or total exposure of oxycodone, hydrocodone or tramadol, so the effect on these opioids is not established.

What the label supports is narrower: tirzepatide has the potential to affect the absorption of oral medicines, the effect is biggest around the first dose, and it diminishes with continued dosing [1]. Any statement that a specific opioid will peak later, peak lower or last longer on Zepbound goes beyond what has been measured.

Does tramadol behave differently?

Tramadol is a Schedule IV opioid that the body converts to M1, a more potent mu-opioid agonist, through the liver enzyme CYP2D6. How much M1 a person makes varies with their CYP2D6 activity.

Tirzepatide is not handled by that system: it is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the fatty diacid and amide hydrolysis, and the label reports low in vitro potential to inhibit or induce CYP enzymes [1]. The Zepbound label does not identify a CYP-mediated interaction between tirzepatide and tramadol. Whether delayed absorption changes tramadol or M1 exposure has not been measured.

Do the stomach and bowel side effects add up?

Both drug classes can cause nausea, vomiting and constipation on their own [1][3].

In the pooled Zepbound weight-management trials (958 people on placebo; 630 on 5 mg, 948 on 10 mg and 941 on 15 mg), nausea occurred in 25%, 29% and 28% on Zepbound versus 8% on placebo, vomiting in 8%, 11% and 13% versus 2%, and constipation in 17%, 14% and 11% versus 5% [1]. Any gastrointestinal adverse reaction was reported in 56% of people on every Zepbound dose versus 30% on placebo, and severe gastrointestinal reactions in 1.7%, 2.5% and 3.1% versus 1% [1]. The label says Zepbound is not recommended in people with severe gastroparesis [1].

On the opioid side, a review estimates that up to 40% of people taking opioids develop constipation, and another review describes it as a consequence of opioid action on receptors in the gut [2][4]. These figures come from separate sources; neither is a study of Zepbound taken with an opioid, so the combined rate of gastrointestinal effects is unknown.

What about sedation and breathing?

Zepbound's labeled mechanism is activation of the GIP and GLP-1 receptors, and its drug interactions section addresses absorption of oral medicines rather than sedation [1]. In the Zepbound trials, dizziness was reported in 4%, 5% and 4% on the 5, 10 and 15 mg doses versus 2% on placebo, and fatigue in 5%, 6% and 7% versus 3% [1].

The opioid's own sedation warning is already in place. In August 2016 the FDA required boxed warnings on opioid analgesics, opioid cough products and benzodiazepines, nearly 400 products in total, describing extreme sleepiness, respiratory depression, coma and death when opioids are combined with benzodiazepines or other CNS depressants, including alcohol [3]. Observational data on the opioid-benzodiazepine combination: among 315,428 privately insured adults who filled an opioid prescription, concurrent benzodiazepine use was associated with an adjusted odds ratio of 2.14 (95% CI 2.05 to 2.24) for an emergency visit or hospital admission for opioid overdose [5].

Zepbound is not part of that warning. Whether it adds anything to opioid sedation is unknown.

Surgery and anesthesia

The Zepbound label reports pulmonary aspiration during general anesthesia or deep sedation in patients receiving GLP-1 receptor agonists and instructs patients to inform healthcare providers about planned surgeries or procedures [1].